Pathogen reduction treatment using riboflavin and ultraviolet light impairs platelet reactivity toward specific agonists in vitro

Transfusion

Volumn 54, Issue 9, 2014, Pages 2292-2300

  Zeddies, Sabrina ^a   De Cuyper, Iris M ^a   Van Der Meer, Pieter F ^b   Daal, Brunette B ^b   De Korte, Dirk ^a,b   Gutiérrez, Laura ^a   Thijssen Timmer, Daphne C ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Department of Blood Cell Research Sanquin Research and Landsteiner Laboratory University of Amsterdam ^*  (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CONVULXIN; GLUCOSE; OXYGEN; PADGEM PROTEIN; PHORBOL 13 ACETATE 12 MYRISTATE; RIBOFLAVIN; RISTOCETIN; THROMBOCYTE FACTOR 4; COLLAGEN;

ARTICLE; CELL SPREADING; CONTROLLED STUDY; DEGRANULATION; EXHAUSTION; FLOW CYTOMETRY; GLUCOSE INTAKE; IN VITRO STUDY; OXYGEN CONSUMPTION; PATHOGEN REDUCTION SYSTEM; PHENOTYPE; PLATELET REACTIVITY; STORAGE; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE RELEASE REACTION; ULTRAVIOLET RADIATION; WESTERN BLOTTING; BLOOD STORAGE; DRUG EFFECTS; HUMAN; METABOLISM; PROCEDURES; RADIATION RESPONSE; THROMBOCYTE TRANSFUSION;

BLOOD PLATELETS; BLOOD PRESERVATION; COLLAGEN; FLOW CYTOMETRY; HUMANS; PLATELET ACTIVATION; PLATELET TRANSFUSION; RIBOFLAVIN; ULTRAVIOLET RAYS;

EID: 84908210572     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12636     Document Type: Article

References (37)

1. Blajchman MA, Goldman M, Baeza F. Improving the bacteriological safety of platelet transfusions. Transfus Med Rev 2004;18:11-24.
2. de Korte D. 10 years experience with bacterial screening of platelet concentrates in the Netherlands. Transfus Med Hemother 2011;38:251-4.
3. Cardo LJ, Salata J, Mendez J, et al. Pathogen inactivation of Trypanosoma cruzi in plasma and platelet concentrates using riboflavin and ultraviolet light. Transfus Apher Sci 2007;37:131-7.
4. Keil SD, Kiser P, Sullivan JJ, et al. Inactivation of Plasmodium spp. in plasma and platelet concentrates using riboflavin and ultraviolet light. Transfusion 2013;53:2278-86.
5. Kitchen A, Mijovic A, Hewitt P. Transfusion-transmitted malaria: current donor selection guidelines are not sufficient. Vox Sang 2005;88:200-1.
6. te Boekhorst PA, Beckers EA, Vos MC, et al. Clinical significance of bacteriologic screening in platelet concentrates. Transfusion 2005;45:514-9.
7. Kumar V, Lockerbie O, Keil SD, et al. Riboflavin and UV-light based pathogen reduction: extent and consequence of DNA damage at the molecular level. Photochem Photobiol 2004;80:15-21.
8. Dardare N, Platz MS. Binding affinities of commonly employed sensitizers of viral inactivation. Photochem Photobiol 2002;75:561-4.
9. Joshi PC. Comparison of the DNA-damaging property of photosensitised riboflavin via singlet oxygen (1O2) and superoxide radical O2-. mechanisms. Toxicol Lett 1985;26: 211-7.
10. Ruane PH, Edrich R, Gampp D, et al. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 2004; 44:877-85.
11. Goodrich RP, Gilmour D, Hovenga N, et al. A laboratory comparison of pathogen reduction technology treatment and culture of platelet products for addressing bacterial contamination concerns. Transfusion 2009;49:1205-16.
12. AuBuchon JP, Herschel L, Roger J, et al. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion 2005;45:1335-41.
13. Perez-Pujol S, Tonda R, Lozano M, et al. Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates. Transfusion 2005; 45:911-9.
14. Picker SM, Steisel A, Gathof BS. Cell integrity and mitochondrial function after Mirasol-PRT treatment for pathogen reduction of apheresis-derived platelets: results of a three-arm in vitro study. Transfus Apher Sci 2009;40: 79-85.
15. Johnson L, Winter KM, Reid S, et al. The effect of pathogen reduction technology (Mirasol) on platelet quality when treated in additive solution with low plasma carryover. Vox Sang 2011;101:208-14.
16. Li J, Xia Y, Bertino AM, et al. The mechanism of apoptosis in human platelets during storage. Transfusion 2000;40: 1320-9.
17. Schubert P, Coupland D, Culibrk B, et al. Riboflavin and ultraviolet light treatment of platelets triggers p38MAPK signaling: inhibition significantly improves in vitro platelet quality after pathogen reduction treatment. Transfusion 2013;53:3164-73.
18. Flevaris P, Li Z, Zhang G, et al. Two distinct roles of mitogen-activated protein kinases in platelets and a novel Rac1-MAPK-dependent integrin outside-in retractile signaling pathway. Blood 2009;113:893-901.
19. Mirasol Clinical Evaluation Study Group. A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology. Transfusion 2010;50:2362-75.
20. Stenberg PE, McEver RP, Shuman MA, et al. A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. J Cell Biol 1985; 101:880-6.
21. Furie B, Furie BC, Flaumenhaft R. A journey with platelet P-selectin: the molecular basis of granule secretion, signalling and cell adhesion. Thromb Haemost 2001;86: 214-21.
22. Bigalke B, Lindemann S, Ehlers R, et al. Expression of platelet collagen receptor glycoprotein VI is associated with acute coronary syndrome. Eur Heart J 2006;27:2165-9.
23. Brisson C, Azorsa DO, Jennings LK, et al. Co-localization of CD9 and GPIIb-IIIa (alpha IIb beta 3 integrin) on activated platelet pseudopods and alpha-granule membranes. Histochem J 1997;29:153-65.
24. Cramer EM, Berger G, Berndt MC. Platelet alpha-granule and plasma membrane share two new components: CD9 and PECAM-1. Blood 1994;84:1722-30.
25. Mody M, Lazarus AH, Semple JW, et al. Preanalytical requirements for flow cytometric evaluation of platelet activation: choice of anticoagulant. Transfus Med 1999;9: 147-54.
26. Broos K, De Meyer SF, Feys HB, et al. Blood platelet biochemistry. Thromb Res 2012;129:245-9.
27. Stegner D, Nieswandt B. Platelet receptor signaling in thrombus formation. J Mol Med (Berl) 2011;89: 109-21.
28. De Cuyper IM, Meinders M, van de Vijver E, et al. A novel flow cytometry-based platelet aggregation assay. Blood 2013;121:e70-e80.
29. Schindelin J, Arganda-Carreras I, Frise E, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods 2012;9:676-82.
30. Nieswandt B, Watson SP. Platelet-collagen interaction: is GPVI the central receptor? Blood 2003;102:449-61.
31. Batuwangala T, Leduc M, Gibbins JM, et al. Structure of the snake-venom toxin convulxin. Acta Crystallogr D Biol Crystallogr 2004;60(Pt 1):46-53.
32. Ostrowski SR, Bochsen L, Windelov NA, et al. Hemostatic function of buffy coat platelets in additive solution treated with pathogen reduction technology. Transfusion 2011;51: 344-56.
33. Broos K, Feys HB, De Meyer SF, et al. Platelets at work in primary hemostasis. Blood Rev 2011;25:155-67.
34. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group. N Engl J Med 1997;337:1861-9.
35. Asano H, Lee CY, Fox-Talbot K, et al. Treatment with riboflavin and ultraviolet light prevents alloimmunization to platelet transfusions and cardiac transplants. Transplantation 2007;84:1174-82.
36. Marschner S, Fast LD, Baldwin WM III, et al. White blood cell inactivation after treatment with riboflavin and ultraviolet light. Transfusion 2010;50:2489-98.
37. Johansson PI, Simonsen AC, Brown PN, et al. A pilot study to assess the hemostatic function of pathogen-reduced platelets in patients with thrombocytopenia. Transfusion 2013;53:2043-52.